Recently published research and thought leadership. Precision expert, Jason Shafrin, outlines challenges and potential solutions to improving measurement of value in response to the Institute for Clinical and Economic Review’s (ICER’s) announcement that they will evaluate treatments for unsupported price increases.

Dr. Shafrin argues that value measurement should not be static because our knowledge of a treatment’s value changes as we uncover new real-world evidence over time. Shafrin advocates for increased collection and use of real-world evidence to inform when rigid formularies may be an appropriate cost savings approach and when they may cause significant harm to patients.

See Dr. Shafrin’s full commentary on these issues in the Journal of Clinical Pathways and Managed Care Magazine.